Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Context Therapeutics Inc. - Common Stock
(NQ:
CNTX
)
0.2787
-0.0263 (-8.62%)
Delayed Quote
Updated: 3:49 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Context Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Friday's After-Market Session
↗
August 04, 2023
Via
Benzinga
Context Therapeutics to Participate in Two August 2023 Investor Conferences
August 01, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
July 19, 2023
Via
Benzinga
ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer
↗
June 08, 2023
This year’s 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023) provided a surprising amount of clinical data relevant to biopharma investors.
Via
Benzinga
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
June 05, 2023
Via
AB Newswire
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
June 05, 2023
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
Via
Benzinga
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
May 10, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference
April 18, 2023
Via
ACCESSWIRE
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Difference
↗
April 14, 2023
Context Therapeutics Inc. (NASDAQ: CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors by harnessing novel and innovative treatment targets such as Claudin 6...
Via
Benzinga
Context Therapeutics to Participate in Two April 2023 Investor Conferences
April 03, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
↗
March 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
March 23, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
March 23, 2023
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning!
Via
InvestorPlace
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
March 22, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 15, 2023
Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET
From
Context Therapeutics Inc.
Via
GlobeNewswire
$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
↗
February 22, 2023
The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Context Therapeutics And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
↗
February 14, 2023
The Dow Jones closed higher by more than 370 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Insiders Buying AmeriServ Financial And 2 Other Penny Stocks
↗
February 07, 2023
The Dow Jones dropped by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...
Via
Benzinga
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
February 06, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Higher By 42%; Here Are 20 Stocks Moving Premarket
↗
February 01, 2023
Gainers
Via
Benzinga
Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors' Attention Today
↗
January 31, 2023
Major Wall Street indices closed over 1% higher on Tuesday, led by upbeat corporate earnings and expectations that the Federal Reserve will slow down its rate hike pace as the centr
Via
Benzinga
Dow Surges Over 200 Points; Pfizer Issues Weak Forecast
↗
January 31, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.63% to 33,931.13 while the NASDAQ rose 1.20% to 11,529.99. The S&P...
Via
Benzinga
Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies
↗
January 31, 2023
Context Therapeutics Inc (NASDAQ: CNTX) shares are trading higher by 60.32% to $1.10 Tuesday afternoon after the company announced its clinical trial collaborator, Stemline Therapeutics, received...
Via
Benzinga
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
January 31, 2023
Gainers
Via
Benzinga
Dow Turns Higher; Nasdaq Jumps 100 Points
↗
January 31, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 0.19% to 33,781.23 while the NASDAQ rose 0.90% to 11,496.13. The S&P...
Via
Benzinga
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
January 31, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying
↗
January 31, 2023
The Nasdaq dropped more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...
Via
Benzinga
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
↗
January 24, 2023
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
↗
January 19, 2023
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
January 09, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
